Nilotinib Viatris (Nilotinib)

Nilotinib is used to treat chronic myeloid leukemia, targeting the BCR‑ABL driven disease process.

• Chronic phase chronic myeloid leukemia: reduces leukemic cell proliferation and improves hematologic and cytogenetic response.
• Accelerated phase chronic myeloid leukemia: achieves disease control when prior therapy is insufficient.
• Blast phase chronic myeloid leukemia: provides targeted inhibition of BCR‑ABL to induce remission.

• Nilotinib selectively binds to the ATP‑binding site of the BCR‑ABL tyrosine kinase, stabilizing the inactive conformation of the enzyme. By preventing phosphorylation of downstream substrates, it blocks signaling pathways that drive proliferation and survival of malignant leukemic cells. The drug also inhibits related kinases such as KIT and PDGFR, contributing to its antineoplastic activity. This targeted inhibition results in decreased tumor burden and can restore normal hematopoiesis.

Nilotinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools that may be watery.
• Headache: dull or throbbing pain.
• Rash: skin redness or itching.
• Fatigue: feeling unusually tired.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• Cardiovascular events: chest pain, heart failure, or arterial occlusion.
• QT interval prolongation: risk of serious arrhythmias.
• Pancreatitis: severe abdominal pain with elevated enzymes.
• Hepatotoxicity: significant liver enzyme elevations.
• Severe infections: opportunistic bacterial or fungal infections.

When prescribing Nilotinib, clinicians should consider several precautionary measures to ensure patient safety.

• Baseline cardiac assessment: evaluate ECG and cardiovascular risk factors.
• Monitor blood counts: perform regular complete blood count tests.
• Assess liver function: check hepatic enzymes periodically.
• Check electrolytes: especially potassium and magnesium to reduce QT risk.
• Avoid concomitant strong CYP3A4 inhibitors: may increase drug exposure.
• Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Nilotinib interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib plasma levels.
• QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of cardiac arrhythmia.
• Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug exposure.
• Warfarin: may require INR monitoring for anticoagulation stability.
• CYP3A4‑metabolized statins (e.g., simvastatin): monitor for myopathy or rhabdomyolysis.